Conflicts of interest in medicine, or making the dynamics of industrial influence transparent (notice n° 582653)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01726cam a2200205 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121141606.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Hauray, Boris |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Conflicts of interest in medicine, or making the dynamics of industrial influence transparent |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 70 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Since the mid-twentieth century, a particular social category—conflict of interest—has dominated our thinking on the influence of pharmaceutical companies in the world of medicine. Initially applied to issues of expertise, it was then mobilized to consider the biases of scientific publications, before targeting the multiple facets of the presence of pharmaceutical manufacturers in medical activity. The success of this category reflects several social processes: the important place occupied by healthcare professionals in society, doubts over the heteronomy created by their increasingly obvious links with economic players, a health democratization movement (questioning of medical authority, mobilization of collectives and associations), and attempts to restore trust by regulating these conflicts of interest. While this dissemination has made it possible to implement policies aimed at limiting situations of conflict of interest, it has often led to the introduction of various policies geared toward making the dynamics of influence transparent. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | médicament |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | transparence |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | conflit d’intérêts |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | influence |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Les Tribunes de la santé | o 79 | 1 | 2024-04-17 | p. 15-23 | 1765-8888 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-les-tribunes-de-la-sante-2024-1-page-15?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-les-tribunes-de-la-sante-2024-1-page-15?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux